Company Profile
MPA Technical Devices Srl is an Italian company specializing in designing and manufacturing top quality and accurate dosing systems.
We achieve the highest standards of precision for dosing all kinds of pharmaceutical substances thanks to over 20 years of experience, a technologically advanced workshop and constant innovation in design. We aim for tailored solutions designed to meet our customers needs and requirements.
Engineering & Design
A highly skilled team of designers can develop customized projects starting from the specifications of the pharmaceutical machine or from the characteristics of the liquids to be dosed. We ensure customer-focused advice, we analyse each problem and propose customized solutions to optimise the performance of the entire production line. It is also possible to re-design or to improve parts or existing systems, to achieve the best results based on users’ feedbacks. The final products are complete with surface treatments as well as special coatings. Components are laser marked on customer request. MPA Technical Devices offers a comprehensive service, support and technical advice from design to final installation.
Company Philosophy
Our goal is to ensure long service life and perfection in every one of our products.
We aim for the highest levels of dosing accuracy and precision since we strongly believe that details lead to perfection in terms of quality and reliability.
“Details make perfection, and perfection is not a detail.” – Leonardo da Vinci
Quality & Traceability
MPA Technical Devices has always used Food&Pharma regulations compliant material coming from European steelworks and manufacturers MOCA or FDA certified, ensuring maximum quality of products thanks to strict controls on raw materials.
On delivery, we check and cross reference each raw material bar to the corresponding certificate number. When the material is cut, the certificate number is linked to the workpiece, achieving in this way a real traceability for each component of our products.
The final product must meet the highest quality standards monitored with appropriate measuring equipment. Products certifications include the tests reports carried out.
Scanning an optional QR code on the product, our customers can have immediate access from their tablet or smartphone to the 3.1 certificates, special coatings, treatments, quality and roughness reports.
We consider quality and transparency of primary importance: for this reason, we regularly test the materials and coatings of our products in independent and ISO certified laboratories, making the reports available to our customers.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...